BR112023022133A2 - Uso de um anticorpo anti-cd19 para tratar miastenia gravis - Google Patents

Uso de um anticorpo anti-cd19 para tratar miastenia gravis

Info

Publication number
BR112023022133A2
BR112023022133A2 BR112023022133A BR112023022133A BR112023022133A2 BR 112023022133 A2 BR112023022133 A2 BR 112023022133A2 BR 112023022133 A BR112023022133 A BR 112023022133A BR 112023022133 A BR112023022133 A BR 112023022133A BR 112023022133 A2 BR112023022133 A2 BR 112023022133A2
Authority
BR
Brazil
Prior art keywords
antibody
myasthenia gravis
treat
treat myasthenia
inebilizumab
Prior art date
Application number
BR112023022133A
Other languages
English (en)
Inventor
Eliezer Katz
N Ratchford John
Liron Abuhsira
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of BR112023022133A2 publication Critical patent/BR112023022133A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

uso de um anticorpo anti-cd19 para tratar miastenia gravis. métodos para usar um anticorpo anti-cd19 para tratar doença autoimune são divulgados neste documento. em particular, a divulgação fornece o uso de inebilizumabe, um anticorpo monoclonal igg1 kappa humanizado, otimizado por afinidade e afucosilado para tratar a miastenia gravis.
BR112023022133A 2021-05-07 2022-05-06 Uso de um anticorpo anti-cd19 para tratar miastenia gravis BR112023022133A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185613P 2021-05-07 2021-05-07
US202263303655P 2022-01-27 2022-01-27
PCT/US2022/028063 WO2022236047A1 (en) 2021-05-07 2022-05-06 Use of an anti-cd19 antibody to treat myasthenia gravis

Publications (1)

Publication Number Publication Date
BR112023022133A2 true BR112023022133A2 (pt) 2023-12-26

Family

ID=81846343

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022133A BR112023022133A2 (pt) 2021-05-07 2022-05-06 Uso de um anticorpo anti-cd19 para tratar miastenia gravis

Country Status (9)

Country Link
EP (1) EP4333987A1 (pt)
JP (1) JP2024518410A (pt)
KR (1) KR20240004367A (pt)
AU (1) AU2022270697A1 (pt)
BR (1) BR112023022133A2 (pt)
CA (1) CA3217586A1 (pt)
IL (1) IL308296A (pt)
MX (1) MX2023012703A (pt)
WO (1) WO2022236047A1 (pt)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
IL114909A (en) 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
ES2609016T3 (es) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
DK1436003T3 (da) 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
DK1558648T3 (da) 2002-10-17 2012-04-23 Genmab As Humane monoklonale antistoffer mod cd20
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
AU2004251679C1 (en) 2003-06-05 2009-05-28 Genentech, Inc. Combination therapy for B cell disorders
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
MX2010004219A (es) * 2007-10-19 2010-08-09 Seattle Genetics Inc Agentes de enlace de cd19 y usos de los mismos.
JP2012518404A (ja) * 2009-02-23 2012-08-16 グレンマーク・ファーマシューティカルズ・エスエー Ｃｄ１９に結合するヒト化抗体及びその使用
CN106794231A (zh) 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病（cll）的治疗
WO2017148880A1 (en) 2016-03-01 2017-09-08 F. Hoffmann-La Roche Ag Obinutuzumab variants having altered cell death induction
MX2021012870A (es) * 2019-04-24 2022-01-18 Viela Bio Inc Uso de un anticuerpo anti cúmulo de diferenciación 19 (cd19) para tratar enfermedades autoinmunitarias.

Also Published As

Publication number Publication date
WO2022236047A1 (en) 2022-11-10
WO2022236047A9 (en) 2023-09-21
CA3217586A1 (en) 2022-11-10
JP2024518410A (ja) 2024-05-01
IL308296A (en) 2024-01-01
KR20240004367A (ko) 2024-01-11
AU2022270697A1 (en) 2023-10-19
EP4333987A1 (en) 2024-03-13
MX2023012703A (es) 2023-11-21

Similar Documents

Publication Publication Date Title
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
ECSP078026A (es) Anticuerpos anti-cd40 humanizados y sus métodos de uso
EA201890302A1 (ru) Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
PE20180950A1 (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
NO20074474L (no) Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav
GT200900002A (es) Anticuerpo antagonista para el tratamiento del cancer
EA201792657A1 (ru) Связывающие lag-3 молекулы и способы их применения
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
PE20220278A1 (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
AR052284A1 (es) Variantes de un anticuerpo y usos de las mismas
AR081750A1 (es) Anticuerpos anti-cd40
BR112018010385A2 (pt) anticorpo, receptor de antígeno quimérico, ácido nucleico, célula recombinante, processo para produção de um anticorpo ou um receptor de antígeno quimérico, composição, e, método para detecção de uma célula que expressa cll-1, para diagnóstico de uma doença, para inibição de divisão da célula e para tratamento de um câncer.
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
BR112019004990A2 (pt) anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
CL2023000499A1 (es) Proteínas que comprenden dominios de unión al antígeno de la hk2 y sus usos.
BR112021020924A2 (pt) Uso de um anticorpo anti-cd19 para tratar doença autoimune
DK1641828T3 (da) Anti-HGF-R-antistoffer og deres anvendelse
EA202091228A1 (ru) Антитела, специфичные к иммуноглобулин-подобному транскрипту 3 (ilt3), и их применение
EP3825334A4 (en) HUMANIZED MONOCLONAL ANTIBODY ANTI-HER3
TR201819828T4 (tr) Anti-fosfolipaz d4 antikoru.
NZ595863A (en) Antibodies to egfl7 and methods for their use
EA202191231A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ
MX2023009615A (es) Moleculas de union anti-cd123 y usos de estas.